Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
This locus encodes a subunit of ATP-dependent chromatin-remodeling complexes. Additionally we are shipping Polybromo 1 Proteins (12) and Polybromo 1 Kits (3) and many more products for this protein.
Showing 10 out of 40 products:
Human Polyclonal PBRM1 Primary Antibody for ICC, IF - ABIN256705
Burrows, Smogorzewska, Elledge: Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. in Proceedings of the National Academy of Sciences of the United States of America 2010
Show all 3 references for ABIN256705
Chicken Polyclonal PBRM1 Primary Antibody for WB - ABIN2781052
Xia, Nagase, Montia, Kalachikov, Keniry, Su, Memeo, Hibshoosh, Parsons: BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. in Cancer research 2008
Human Polyclonal PBRM1 Primary Antibody for IP - ABIN256704
Niimi, Chambers, Downs, Lehmann: A role for chromatin remodellers in replication of damaged DNA. in Nucleic acids research 2012
Synthetic lethality screening identifies TIP60 (show KAT5 Antibodies)-dependent radiation sensitivity in the absence of BAF180.
Functionally, suppression of PBRM1 expression promoted cell proliferation and cell cycle progression
PBRM1 re-expression led to upregulation of genes involved in cellular adhesion, carbohydrate metabolism, apoptotic process and response to hypoxia, and a downregulation of genes involved in different stages of cell division.
Use bioinformatic tools to predict the molecular effects of all mutations lying in PBRM1 genes.
PBRM1 might involve in the development and progression of breast cancer as a tumor suppressor, and thereby may be a valuable prognostic marker for breast cancer patients.
our data describe a close interrelation between p53 (show TP53 Antibodies) and PBRM1 in renal cell carcinomas
PBRM1 expression identified 4 clinical subgroups of patients with clear cell renal cell carcinoma (show MOK Antibodies) who had divergent clinical outcomes.
PBRM1 could block the G2/M transition by repressing cyclin B1 (show CCNB1 Antibodies). The data indicated that PBRM1 functions as a tumor suppressor in bladder cancer by repressing cyclin B1 (show CCNB1 Antibodies) expression.
Decreased expression of PBRM1 predicts unfavorable clinical outcome in patients with ccRCC.
We report, for the first time, co-inactivation and frequent mutations of SMARCB1 (show SMARCB1 Antibodies), SMARCA2 (show SMARCA2 Antibodies) and PBRM1 in MRTs.
Data demonstrate a function for BAF180 in promoting genome stability that is distinct from its well-characterized role in transcriptional regulation.
BAF180 is a repressor of IL-10 (show IL10 Antibodies) transcription in Th2 cells and suggest that the differential recruitment of different SWI (show SMARCA1 Antibodies)/SNF (show SNRPA Antibodies) subtypes can have direct consequences on chromatin structure and gene transcription.
BAF180 is critical for coronary vessel formation.
This locus encodes a subunit of ATP-dependent chromatin-remodeling complexes. The encoded protein has been identified as in integral component of complexes necessary for ligand-dependent transcriptional activation by nuclear hormone receptors. Mutations at this locus have been associated with primary clear cell renal cell carcinoma.
, protein polybromo-1
, BRG1-associated factor 180
, glutamate receptor interacting protein 2
, polybromo 1 protein